# Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

> **NCT05621759** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 27 (actual)

## Conditions studied

- Graft Vs Host Disease

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Abatacept
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT05621759
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-07
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621759, "Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05621759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*